awmsg logo



tenofovir disoproxil fumarate (Viread®)


Reference No. 2006

Publication date:
08/05/2014


Appraisal information

tenofovir disoproxil fumarate (Viread®) 245 mg film-coated tablet
tenofovir disoproxil fumarate (Viread®) 33 mg/g granules


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 22/01/2014
AWMSG meeting date: 19/02/2014
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0714
Ministerial ratification: 07/05/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tenofovir disoproxil (as fumarate) (Viread®) 245 mg film-coated tablets are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus. Tenofovir disoproxil (as fumarate) (Viread®) 33 mg/g granules are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with evidence of lamivudine-resistant hepatitis B virus.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download